Hämatologische Neoplasien beim älteren Menschen

Hämatologische Tumoren betreffen vor allem ältere Patienten. Neben ihrer Tumorerkrankung leiden diese häufig an Begleiterkrankungen, die mit Polypharmazie und funktionellen Einschränkungen einhergehen. Dabei schwankt die Prävalenz geriatrischer Syndrome in Abhängigkeit von der jeweiligen hämatologischen Neoplasie und der klinischen Situation.

• Literatur

• 1 Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum für Krebsregisterdaten, Robert Koch-Institut. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html
• 2 Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res 2014; 38: 275-283
• 3 Decoster L, Van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol 2015; 26: 288-300
• 4 Wildiers H, Heeren P, Puts M. et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014; 32: 2595-2603
• 5 Hurria A, Togawa K, Mohile SG. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457-3465
• 6 Extermann M, Boler I, Reich RR. et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377-3386
• 7 Magnuson A, Allore H, Cohen HJ. et al. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. J Geriatr Oncol 2016; 7: 242-248
• 8 Goede V. New Developments in Geriatric Oncology. Dtsch Med Wochenschr 2017; 142: 163-168
• 9 Krug U, Röllig C, Koschmieder A. et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008
• 10 Klepin HD. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clin Geriatr Med 2016; 32: 155-173
• 11 Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep 2016; 6: 1-7
• 12 Gugliotta G, Castagnetti F, Apolinari M. et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 2014; 74: 627-643
• 13 Russo D, Malagola M, Skert C. et al. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J 2015; 5: e347
• 14 Eichhorst B, Robak T, Montserrat E. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v78-v84
• 15 Strati P, Parikh SA, Chaffee KG. et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 2017; 178: 394-402
• 16 Stauder R, Eichhorst B, Hamaker ME. et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 2017; 28: 218-227
• 17 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
• 18 Tucci A, Martelli M, Rigacci L. et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 2015; 56: 921-926
• 19 Böll B, Goergen H, Behringer K. et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189-2192
• 20 Gopal AK, Bartlett NL, Forero-Torres A. et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma 2014; 55: 2328-2334
• 21 Palumbo A, Bringhen S, Mateos MV. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125: 2068-2074